Lucintel's latest market report analyzed that prostate health provides attractive opportunities in pharmacies and e-commerce stores. The prostate health market is expected to reach $58.9 billion by 2028 with a CAGR of 9.1%. In this market, prostate cancer is the largest segment by disease indication, whereas e-commerce store is largest by disease indication.
Download Brochure of this report by clicking on https://www.lucintel.com/prostate-health-market.aspx
Based on disease indication, the prostate health market is segmented into prostate cancer, prostatitis, alpha blockers, benign prostate hyperplasia, and others. The prostate cancer segment accounted for the largest share of the market in 2023 and is expected to register the highest CAGR during the forecast period, due to because augmenting cancer cases has influenced the usage of immunotherapies to inhibit prostate cancer cells from spreading. Also, hormone therapy is generally used to effectively treat cancer at the initial stage.
Browse in-depth TOC on “Prostate Health Market”
100 – Figures/Tables
150 – Pages
The Prostate Health Market is marked by the presence of several big and small players. Some of the prominent players offering prostate health include Eli Lilly and Company, Pfizer, Merck & Co., Abbott, Endo Pharmaceuticals, GlaxoSmithKline PLC, Siemens Healthcare, Amgen, and AstraZeneca.
Request Sample Report:
https://www.lucintel.com/prostate-health-market.aspx
This unique research report will enable you to make confident business decisions in this globally competitive marketplace. For a detailed table of contents, contact Lucintel at +1-972-636-5056 or click on this link helpdesk@lucintel.com.
About Lucintel
Lucintel, the premier global management consulting and market research firm, creates winning strategies for growth. It offers market assessments, competitive analysis, opportunity analysis, growth consulting, M&A, and due diligence services to executives and key decision-makers in a variety of industries. For further information, visit www.lucintel.com.